Leading the Charge
Imagine being a freshman at college on a basketball scholarship. You know this scholarship is your ticket out of your small mining town and on to a brighter future. Now imagine being told that you might lose your foot due to a misdiagnosis of an ankle injury.That is exactly what happened to Frank Washenitz, now VP, Head of Global and NA Sales Enhancement at Mylan. Luckily for Frank, he did not lose that ankle. The experience, however, left him sensitive to the fragility of health, the need for improvement in medicine and a desire to make a difference.“Looking back, I never really had a plan to be in pharma training, but ...
Source: EyeForPharma - December 14, 2018 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Leading the Charge
Imagine being a freshman at college on a basketball scholarship. You know this scholarship is your ticket out of your small mining town and on to a brighter future. Now imagine being told that you might lose your foot due to a misdiagnosis of an ankle injury.That is exactly what happened to Frank Washenitz, now VP, Head of Global and NA Sales Enhancement at Mylan. Luckily for Frank, he did not lose that ankle. The experience, however, left him sensitive to the fragility of health, the need for improvement in medicine and a desire to make a difference.“Looking back, I never really had a plan to be in pharma training, but ...
Source: EyeForPharma - December 14, 2018 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Growing Pains
There is no one-size-fits-all model for pharma companies seeking input from patients. There was no blueprint when companies took their first tentative steps a few years ago and there is none now as they enter the next era – scaling up patient-centric efforts to become business as usual.“When I talk to patient organizations, many times they ask, Why does wanting better patient outcomes require a culture shift in pharma?” says Laura McKeaveney, Head of Global Patient Advocacy at Novartis. “But that’s not what requires the culture shift.”People who work in pharma want better patient outcomes, she says, “but if y...
Source: EyeForPharma - December 12, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news
VBCs: Are They Working?
As an observer, it can be difficult to find out what ’s happening with value-based contracts (VBCs). The fanfare that accompanies the announcement of a deal invariably gives way to a long period of silence, a good sign if you subscribe to the mantra that no news is good news, but if you don’t, there is cause for concern.The smattering of reports on the topic suggest that green shoots are emerging. A recent survey of 120 payers conducted by the ORC International and commissioned by Change Healthcare, found that payers reported an average saving in medical costs of 5.6% from VBC strategies with an accompanying 77% improv...
Source: EyeForPharma - December 12, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news
Made to Measure
Often attributed to management guru Peter Drucker but perhaps coined first by 19th century scientist William Thompson, Lord Kelvin, there is more to this famous quotation than first meets the eye.On the one hand, it is common sense – you do, you measure, you improve. But, on the other hand, can your activity be measured? Do the tools and metrics even exist? And, are you measuring the right things? Measuring can be a tricky business.Patient-centricity has transformed pharma, yet few companies effectively measure the impact of their patient engagement activities let alone track the shift in their people towards a patients-...
Source: EyeForPharma - December 11, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news
Calling the Shots?
The USA has the highest drug costs in the world, and they are increasing at the fastest rate too. With one in five Americans saying they have been forced to leave a prescription unfilled due to high costs, the situation is clearly unsustainable.Payers and pharmacy benefit managers (PBMs), themselves facing increased criticism for blocking access to important medicines, are taking action by demanding that pharma companies justify the cost – and value – of their new medicines.“There is a point where a government, an employer or a healthcare plan has a finite amount of resources to spend,” says Brian Henry, VP Corpora...
Source: EyeForPharma - December 10, 2018 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
